Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Clinical trial NCT05508347 · RECRUITING

Trial details

NCT number: NCT05508347
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma

Start date: 2022-04-20
Primary completion: 2025-10-30
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.